Taking a broad and long-term view to establish China Center for Evidence Based Traditional Chinese Medicine (CCEBTCM)_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Yongyan , HUANG Luqi

China Academy of Chinese Medical Sciences, Beijing, 100700, P.R.China;

Corresponding?author：

Keywords：

China Center for Evidence Based Traditional Chinese Medicine (CCEBTCM); Traditional Chinese medicine; Evidence-based medicine; Inheritance and innovation; Research teams resource integration; Development consensus

DOI：

10.7507/1672-2531.201908098

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Clinical efficacy evaluation is important for the development of traditional Chinese medicine (TCM). In view of the existing accumulation and current situation of the TCM clinical efficacy evaluation, based on the international perspective, and taking the rational and objective evaluation of TCM clinical efficacy and safety as the foundation, in order to enhance TCM evidence level to support clinical decision-making and promote TCM industry and TCM internationalization development, the State Administration of TCM entrusted China Academy of Chinese Medical Sciences to establish China Center for Evidence Based Traditional Chinese Medicine (CCEBTCM). CCEBTCM is expected to optimize the allocation of evidence-based research resources in TCM field to further integrate advantages of evidence-based TCM research teams, promote consensus on evidence-based TCM standards, share evidence-based TCM data or information and lead cultural exchanges between Chinese and overseas. In this way, the status and influence of TCM in the world will be enhanced so that it can better serve global health.

Citation： WANG Yongyan, HUANG Luqi. Taking a broad and long-term view to establish China Center for Evidence Based Traditional Chinese Medicine (CCEBTCM). Chinese Journal of Evidence-Based Medicine, 2019, 19(10): 1131-1137. doi: 10.7507/1672-2531.201908098 Copy

1.	Spriet A, Simon P, Dupin-Spriet T. Methodology of clinical drug trials. New York: Karger, 1985: 14-15.
2.	青蒿素結構研究協作組. 一種新型的倍半萜內酯—青蒿素. 科學通報, 1977, 22(3): 142.
3.	Hesketh T, Zhu WX. Traditional Chinese medicine: one country, two systems. BMJ, 1997, 315(7100): 115-117.
4.	陳可冀, 錢振淮, 張問渠, 等. 精制冠心片雙盲法治療冠心病心絞痛 112 例療效分析. 中華心血管病雜志, 1982, 10(2): 85-89.
5.	Tang JL, Zhan SY, Ernst E. Review of randomised controlled trials of traditional Chinese medicine. BMJ, 1999, 319(7203): 160-161.
6.	李幼平, 李靜, 孫鑫, 等. 循證醫學在中國的起源與發展: 獻給中國循證醫學20周年. 中國循證醫學雜志, 2016, 16(1): 2-6.
7.	王永炎, 劉保延, 謝雁鳴. 應用循證醫學方法構建中醫臨床評價體系. 中國中醫基礎醫學雜志, 2003, 9(3): 17-23.
8.	陳可冀, 宋軍. 循證醫學的提出對中西醫結合的啟發. 中國中西醫結合雜志, 1999, 19(11): 643.
9.	張伯禮. 辨證論治與循證醫學. 中國循證醫學雜志, 2002, 2(1): 1-3.
10.	李幼平, 劉鳴. 循證醫學與中醫藥現代化. 中國中醫藥信息雜志, 1999, 8(12): 14-16, 32.
11.	張曉雨, 陳詩琪, 李承羽, 等. 循證中醫藥學理論研究與應用實踐. 中國循證醫學雜志, 2018, 18(1): 86-91.
12.	Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med, 2013, 2013: 1-9.
13.	劉建平. 循證醫學. 人民衛生出版社, 2012.
14.	劉建平, 商洪才. 循證中醫藥. 人民衛生出版社, 2018.
15.	Zhang X, Tian R, Yang Z, et al. Quality assessment of clinical trial registration with traditional Chinese medicine in WHO registries. BMJ Open, 2019, 9(2): e025218.
16.	Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med, 2017, 167(2): W7-W20.
17.	Liu Z, Liu Y, Xu H, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA, 2017, 317(24): 2493-2501.
18.	Zhao L, Chen J, Li Y, et al. The long-term effect of acupuncture for migraine prophylaxis: a randomized clinical trial. JAMA Intern Med, 2017, 177(4): 508-515.
19.	Liu Z, Yan S, Wu J, et al. Acupuncture for chronic severe functional constipation: a randomized trial. Ann Intern Med, 2016, 165(11): 761-769.
20.	Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza. Ann Intern Med, 2011, 155(4): 217-225.
21.	Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin Capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
22.	Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol, 2008, 101(12): 1689-1693.
23.	Song Y, Yao C, Yao Y, et al. XueBiJing injection versus placebo for critically Ⅲ patients with severe community-acquired pneumonia: a randomized controlled trial. Crite Care Med,, 2019, 47(9): e735-e743.
24.	王忠, 王永炎. 中藥上市后臨床再評價研究. 中國中藥雜志, 2007, 32(1): 84-86.
25.	楊薇, 謝雁鳴, 王永炎. 中醫藥臨床實效研究—中藥注射劑注冊登記式醫院集中監測方案解讀. 中國中藥雜志, 2012, 37(18): 2683-2685.
26.	趙晨, 田貴華, 王燕平, 等. 涵蓋科學觀與人文觀的循證醫學發展—兼談循證中醫藥學科的未來前景. 中國循證醫學雜志, 2019, 19(2): 232-237.
27.	Ahn K. The worldwide trend of using botanical drugs and strategies for developing global drugs. BMB Rep, 2017, 50(3): 111-116.
28.	楊瑾, 加茂智嗣, 能瀨愛加. 漢方藥在日本的發展現狀. 中草藥, 2016, 47(15): 2771-2774.
29.	中華中醫藥學會. 中醫藥重大科學問題和工程技術難題. 中醫雜志, 2019, 60(12): 991-1000.

1. Spriet A, Simon P, Dupin-Spriet T. Methodology of clinical drug trials. New York: Karger, 1985: 14-15.
2. 青蒿素結構研究協作組. 一種新型的倍半萜內酯—青蒿素. 科學通報, 1977, 22(3): 142.
3. Hesketh T, Zhu WX. Traditional Chinese medicine: one country, two systems. BMJ, 1997, 315(7100): 115-117.
4. 陳可冀, 錢振淮, 張問渠, 等. 精制冠心片雙盲法治療冠心病心絞痛 112 例療效分析. 中華心血管病雜志, 1982, 10(2): 85-89.
5. Tang JL, Zhan SY, Ernst E. Review of randomised controlled trials of traditional Chinese medicine. BMJ, 1999, 319(7203): 160-161.
6. 李幼平, 李靜, 孫鑫, 等. 循證醫學在中國的起源與發展: 獻給中國循證醫學20周年. 中國循證醫學雜志, 2016, 16(1): 2-6.
7. 王永炎, 劉保延, 謝雁鳴. 應用循證醫學方法構建中醫臨床評價體系. 中國中醫基礎醫學雜志, 2003, 9(3): 17-23.
8. 陳可冀, 宋軍. 循證醫學的提出對中西醫結合的啟發. 中國中西醫結合雜志, 1999, 19(11): 643.
9. 張伯禮. 辨證論治與循證醫學. 中國循證醫學雜志, 2002, 2(1): 1-3.
10. 李幼平, 劉鳴. 循證醫學與中醫藥現代化. 中國中醫藥信息雜志, 1999, 8(12): 14-16, 32.
11. 張曉雨, 陳詩琪, 李承羽, 等. 循證中醫藥學理論研究與應用實踐. 中國循證醫學雜志, 2018, 18(1): 86-91.
12. Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med, 2013, 2013: 1-9.
13. 劉建平. 循證醫學. 人民衛生出版社, 2012.
14. 劉建平, 商洪才. 循證中醫藥. 人民衛生出版社, 2018.
15. Zhang X, Tian R, Yang Z, et al. Quality assessment of clinical trial registration with traditional Chinese medicine in WHO registries. BMJ Open, 2019, 9(2): e025218.
16. Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med, 2017, 167(2): W7-W20.
17. Liu Z, Liu Y, Xu H, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA, 2017, 317(24): 2493-2501.
18. Zhao L, Chen J, Li Y, et al. The long-term effect of acupuncture for migraine prophylaxis: a randomized clinical trial. JAMA Intern Med, 2017, 177(4): 508-515.
19. Liu Z, Yan S, Wu J, et al. Acupuncture for chronic severe functional constipation: a randomized trial. Ann Intern Med, 2016, 165(11): 761-769.
20. Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza. Ann Intern Med, 2011, 155(4): 217-225.
21. Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin Capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
22. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol, 2008, 101(12): 1689-1693.
23. Song Y, Yao C, Yao Y, et al. XueBiJing injection versus placebo for critically Ⅲ patients with severe community-acquired pneumonia: a randomized controlled trial. Crite Care Med,, 2019, 47(9): e735-e743.
24. 王忠, 王永炎. 中藥上市后臨床再評價研究. 中國中藥雜志, 2007, 32(1): 84-86.
25. 楊薇, 謝雁鳴, 王永炎. 中醫藥臨床實效研究—中藥注射劑注冊登記式醫院集中監測方案解讀. 中國中藥雜志, 2012, 37(18): 2683-2685.
26. 趙晨, 田貴華, 王燕平, 等. 涵蓋科學觀與人文觀的循證醫學發展—兼談循證中醫藥學科的未來前景. 中國循證醫學雜志, 2019, 19(2): 232-237.
27. Ahn K. The worldwide trend of using botanical drugs and strategies for developing global drugs. BMB Rep, 2017, 50(3): 111-116.
28. 楊瑾, 加茂智嗣, 能瀨愛加. 漢方藥在日本的發展現狀. 中草藥, 2016, 47(15): 2771-2774.
29. 中華中醫藥學會. 中醫藥重大科學問題和工程技術難題. 中醫雜志, 2019, 60(12): 991-1000.

Next Article
Translation and interpretation of the European guideline on management of major bleeding and coagulopathy following trauma (the fifth edition)

Chinese Journal of Evidence-Based Medicine

Taking a broad and long-term view to establish China Center for Evidence Based Traditional Chinese Medicine (CCEBTCM)

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content